Literature DB >> 11070093

Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically.

M Grilli1, E Diodato, G Lozza, R Brusa, M Casarini, D Uberti, R Rozmahel, D Westaway, P St George-Hyslop, M Memo, E Ongini.   

Abstract

A direct pathophysiological role of Familial Alzheimer's Disease (FAD)-associated Presenilin 1 (PS1) mutations in neuronal vulnerability remains a controversial matter. We evaluated the relationship between PS1 and excitotoxicity in four different experimental models of neurotoxicity by using primary neurons from (i) transgenic (tg) mice overexpressing a human FAD-linked PS1 variant (L286V mutation), (ii) tg mice overexpressing human wild-type (wt) PS1, (iii) PS1 knockout mice, and (iv) wt mice in which PS1 gene expression was knocked down by antisense treatment. We found that primary neurons overexpressing mutated PS1 showed an increased vulnerability to both excitotoxic and hypoxic-hypoglycemic damage when compared with neurons obtained from either mice overexpressing human wt PS1 or in wt mice. In addition, reduced excitotoxic damage was obtained in neurons in which PS1 expression was absent or diminished. Data obtained in in vivo experimental models of excitotoxicity partially supported the in vitro observations. Accelerated neuronal death was demonstrated in the hippocampus of mice overexpressing mutated PS1 after peripheral administration of kainic acid in comparison with wt animals. However, measurement of the infarct volume after middle cerebral artery occlusion did not show significant difference between the two animal groups. The results altogether suggest that expression of FAD-linked PS1 variants increases the vulnerability of neurons to a specific type of damage in which excitotoxicity plays a relevant role. In addition, they support the view that reduction of endogenous PS1 expression results in neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070093      PMCID: PMC18848          DOI: 10.1073/pnas.97.23.12822

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Alzheimer's disease presenilin-1 exon 9 deletion and L250S mutations sensitize SH-SY5Y neuroblastoma cells to hyperosmotic stress-induced apoptosis.

Authors:  H Tanii; M Ankarcrona; F Flood; C Nilsberth; N D Mehta; J Perez-Tur; B Winblad; E Benedikz; R F Cowburn
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.

Authors:  M C Chartier-Harlin; F Crawford; H Houlden; A Warren; D Hughes; L Fidani; A Goate; M Rossor; P Roques; J Hardy
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

3.  Brain volume estimation from serial section measurements: a comparison of methodologies.

Authors:  G D Rosen; J D Harry
Journal:  J Neurosci Methods       Date:  1990-11       Impact factor: 2.390

4.  Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis.

Authors:  M P Mattson; H Zhu; J Yu; M S Kindy
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

5.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.

Authors:  A Goate; M C Chartier-Harlin; M Mullan; J Brown; F Crawford; L Fidani; L Giuffra; A Haynes; N Irving; L James
Journal:  Nature       Date:  1991-02-21       Impact factor: 49.962

6.  Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells.

Authors:  D M Kovacs; H J Fausett; K J Page; T W Kim; R D Moir; D E Merriam; R D Hollister; O G Hallmark; R Mancini; K M Felsenstein; B T Hyman; R E Tanzi; W Wasco
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

7.  Alterations in tau immunostaining in the rat hippocampus following transient cerebral ischemia.

Authors:  J W Geddes; C Schwab; S Craddock; J L Wilson; L C Pettigrew
Journal:  J Cereb Blood Flow Metab       Date:  1994-07       Impact factor: 6.200

8.  N-methyl-D-aspartate receptors mediate hypoxic neuronal injury in cortical culture.

Authors:  M P Goldberg; J H Weiss; P C Pham; D W Choi
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

9.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus.

Authors:  E Levy-Lahad; W Wasco; P Poorkaj; D M Romano; J Oshima; W H Pettingell; C E Yu; P D Jondro; S D Schmidt; K Wang
Journal:  Science       Date:  1995-08-18       Impact factor: 47.728

10.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.

Authors:  R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

View more
  10 in total

1.  Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice.

Authors:  Kristal W Boyett; Giovanni DiCarlo; Paul T Jantzen; Jennifer Jackson; Charlotte O'Leary; Donna Wilcock; Dave Morgan; Marcia N Gordon
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

Review 2.  Presenilin transgenic mice as models of Alzheimer's disease.

Authors:  Gregory A Elder; Miguel A Gama Sosa; Rita De Gasperi; Dara L Dickstein; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2009-11-18       Impact factor: 3.270

3.  Presenilin 1 promotes trypsin-induced neuroprotection via the PAR2/ERK signaling pathway. Effects of presenilin 1 FAD mutations.

Authors:  Angeliki M Nikolakopoulou; Anastasios Georgakopoulos; Nikolaos K Robakis
Journal:  Neurobiol Aging       Date:  2016-03-04       Impact factor: 4.673

4.  The presenilin-1 familial Alzheimer's disease mutation P117L decreases neuronal differentiation of embryonic murine neural progenitor cells.

Authors:  Lorenza Eder-Colli; Noelia Abad-Estarlich; Carine Pannetier; Philippe G Vallet; Claude Walzer; Gregory A Elder; Nikolaos K Robakis; Constantin Bouras; Armand Savioz
Journal:  Brain Res Bull       Date:  2009-06-23       Impact factor: 4.077

Review 5.  Transgenic mouse models of Alzheimer's disease.

Authors:  Gregory A Elder; Miguel A Gama Sosa; Rita De Gasperi
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

6.  Familial Alzheimer's Disease Lymphocytes Respond Differently Than Sporadic Cells to Oxidative Stress: Upregulated p53-p21 Signaling Linked with Presenilin 1 Mutants.

Authors:  Joanna Wojsiat; Katarzyna Laskowska-Kaszub; Carolina Alquézar; Emilia Białopiotrowicz; Noemi Esteras; Mykola Zdioruk; Angeles Martin-Requero; Urszula Wojda
Journal:  Mol Neurobiol       Date:  2016-09-19       Impact factor: 5.590

7.  Mouse models of Alzheimer's disease cause rarefaction of pial collaterals and increased severity of ischemic stroke.

Authors:  Hua Zhang; Bo Jin; James E Faber
Journal:  Angiogenesis       Date:  2018-12-05       Impact factor: 9.596

8.  Endogenous expression of FAD-linked PS1 impairs proliferation, neuronal differentiation and survival of adult hippocampal progenitors.

Authors:  Karthikeyan Veeraraghavalu; Se Hoon Choi; Xiaoqiong Zhang; Sangram S Sisodia
Journal:  Mol Neurodegener       Date:  2013-10-20       Impact factor: 14.195

Review 9.  Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?

Authors:  Jan Lewerenz; Pamela Maher
Journal:  Front Neurosci       Date:  2015-12-16       Impact factor: 4.677

Review 10.  Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.

Authors:  Madhuri Chakravarthy; Suxiang Chen; Peter R Dodd; Rakesh N Veedu
Journal:  Theranostics       Date:  2017-09-05       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.